Clinical evaluation of efficacy of infused CDDP dose in superselective intra-arterial chemoradiotherapy for maxillary sinus cancer

• Yoshizaki Tomokazu

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

• Tsukatani Toshiaki

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

• Wakisaka Naohiro

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

• Murono Shigeyuki

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

• Kondo Satoru

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

• Takanaka Tsuyoshi

  Division of Radiology, Graduate School of Medical Science, Kanazawa University

• Furukawa Mitsuru

  Division of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University

Bibliographic Information

Other Title

• 急速動注化学療法による上顎洞癌治療―ＣＤＤＰ投与量との関連について―
• ―CDDP投与量との関連について―

Abstract

To evaluate the treatment efficacy of infused dose of cisplatin in intra-arterial chemoradiotherapy for maxillary sinus cancer, patients treated with superselective chemoradiotherapy were divided into a low-dose group (<450mg/body of cisplatin, n=7, follow-up period 5-60 months, median follow-up 26 months) and a high-dose group (>600mg/body of cisplatin, n=8, follow-up period 10-32 months, median follow-up 19 months). Of 22 cases, 15 cases who had received at least 2 courses of intra-arterial infusion of cisplatin were involved in this study. The high-dose group had a better overall survival rate and progression-free survival although it was not statistically significant. However, 5 of 7 patients in the low-dose group received partial maxillectomy or more invasive salvage surgery whereas none of the high-dose group did (p=0.0138). There was no significant difference of adverse effects in the two groups. These results suggest that 450mg of cisplatin is insufficient to control maxillary sinus cancer but 600mg of cisplatin is beneficial.

Journal

• Toukeibu Gan

  Toukeibu Gan 33 (4), 434-438, 2007

  Japan Society for Head and Neck Cancer

Keywords

• Maxillary sinus cancer
• Intra-arterial chemotherapy
• Cisplatin
• Chemotherapy
• Radiotherapy

Details

• CRID: 1390001205221411072
• NII Article ID: 130004509993
• NII Article ID: 20000855393
• NII Article ID: 10020282497
• NII Book ID: AA11985555
• DOI: 10.5981/jjhnc.33.434
• ISSN: 18818382
• ISSN: 13495747
• ISSN: http://id.crossref.org/issn/13495747
• Web Site: https://search.jamas.or.jp/link/ui/2008119516
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed